| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-09-21 | Alder Biopharmaceuticals (USA - WA) | nomination | CNS diseases - Neurological diseases | Nomination | ||
| 2016-09-20 | Teva Pharmaceutical Industries (Israel) Regeneron Pharmaceuticals (USA - NY) | fasinumab (REGN475) | osteoarthritis pain, chronic pain | development commercialisation |
Rheumatic diseases - Inflammatory diseases – Bone diseases | Development agreement |
| 2016-09-20 | Aegerion Pharmaceuticals (USA - MA) | nomination |
Rare diseases - Genetic diseases - Metabolic diseases | Nomination | ||
| 2016-09-20 | GSK (UK) | nomination |
Nomination | |||
| 2016-09-20 | Alnylam Therapeutics (USA - MA) | establishment of a new subsidiary in the EU |
Rare diseases - Genetic diseases | Establishment of a new subsidiary in the EU | ||
| 2016-09-20 | Basilea Pharmaceutica (Switzerland) Unimedic Pharma | invasive aspergillosis, mucormycosis, severe community-acquired and hospital-acquired pneumonia | distribution | Infectious diseases | Distribution agreement | |
| 2016-09-19 | GE Healthcare (USA - WI) | biopharmaceutical manufacturing campus GE BioPark Cork | construction of new premises |
Technology - Services | Construction of new premises | |
| 2016-09-19 | Adaptimmune (UK) PCT, a Caladrius Company (USA - CA) | SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell products | production manufacturing |
Cancer - Oncology | Production agreement | |
| 2016-09-15 | Teva Pharmaceutical Industries (Israel) Intel (US - CA) | wearable device and machine learning platform | Huntington's disease | development |
Genetic diseases - Neurodegenerative diseases - Rare diseases | Development agreement |
| 2016-09-15 | Lion Biotechnologies (USA - CA) PolyBioCept (Sweden) | combination of cytokines for use in the expansion, selection and enrichment of TIL (tumor infiltrating lymphocyte) products | glioblastoma, pancreatic cancer | licensing
|
Cancer - Oncology | Licensing agreement |
| 2016-09-15 | Lion Biotechnologies (USA - CA) Karolinska University Hospital (Sweden) | TIL (tumor infiltrating lymphocyte) products | glioblastoma, pancreatic cancer | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2016-09-15 | OSE Immunotherapeutics (France) | nomination |
Autoimmune diseases - Cancer - Oncology - Transplantation | Nomination | ||
| 2016-09-15 | Zambon (Italy) | nomination |
Nomination | |||
| 2016-09-15 | Basilea Pharmaceutica (Switzerland) Asahi Kasei Pharma (Japan) | isavuconazole | invasive aspergillosis, mucormycosis | collaboration | Infectious diseases | Collaboration agreement |
| 2016-09-13 | Basilea Pharmaceutica (Switzerland) Grupo Biotoscana (Uruguay) | Cresemba® (isavuconazole) and Zevtera® (ceftobiprole) | invasive aspergillosis, mucormycosis, severe community-acquired and hospital-acquired pneumonia | distribution - licensing | Infectious diseases | Distribution agreement |
| 2016-09-12 | Sanofi (France) Google Life Sciences, now Verily Life Sciences (USA - CA) Onduo (UA - MA) | type 1 diabetes, type 2 diabetes | collaboration joint-venture |
Metabolic diseases | Joint-venture agreement | |
| 2016-09-12 | Oryzon Genomics (Spain) | multiple sclerosis | nomination |
Neurodegenerative diseases - Neuroinflammatory diseases | Nomination | |
| 2016-09-12 | Soligenix (USA - NJ) SciClone (USA - CA) | dusquetide (SGX942) | oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer | licensing |
Cancer - Oncology | Licensing agreement |
| 2016-09-12 | Lonza (Switzerland) Massachusetts Eye and Ear® (USA - MA) | Anc80 and other Anc-AAVs gene therapy products | licensing |
Technology - Services | Licensing agreement | |
| 2016-09-12 | Redhill Biopharma (Israel) Stanford University School of Medicine (USA - CA) | Yeliva™ (ABC294640) | mucositis in head and neck cancer patients undergoing therapeutic radiotherapy | R&D |
Cancer - Oncology | R&D agreement |
